Long-term efficacy and safety of sildenafil was assessed in 1008 patients with erectile dysfunction (ED) enrolled in four flexible-dose (25 -100 mg), open-label, 36-or 52-week extension studies. After 36 and 52 weeks, 92% and 89% of patients felt that treatment with sildenafil had improved their erections. Responses to a Sexual Function Questionnaire indicated that 52 weeks of sildenafil treatment resulted in clinically significant improvements in the duration and firmness of erections, overall satisfaction with sex life, and the frequency of stimulated erections. Commonly reported adverse events (AEs) were headache, flushing, dyspepsia, and rhinitis, which were generally mild to moderate. Reports of abnormal vision were consistent with previous clinical trials. The occurrence of treatment-related cardiovascular AEs, such as hypertension, tachycardia, and palpitation, was < 1%. Discontinuations due to treatment-related AEs were low (2%). Long-term therapy does not diminish the efficacy of sildenafil in patients with ED and remains well tolerated.
Introduction
Erectile dysfunction (ED) has been defined as the inability to achieve and maintain penile erection sufficient for satisfactory sexual performance. 1 In the UK, a study of 109 men aged 16 to over 65 y found that 32% had some difficulty in achieving an erection, and 20% had some difficulty in maintaining an erection. 2 In France, a study of 986 men aged 18 -94 y showed that 42% of men had some degree of ED. 3 The prevalence of ED among 1240 men aged 40 -70 y in a study conducted in the United States was found to be 52%, corresponding to approximately 10 -30 million men. 4 The underlying physiology of penile erection involves neurovascular events that result in the relaxation of the smooth muscle of the corpus cavernosum and associated arterioles followed by an increase in arterial blood flow leading to tumescence. 5, 6 The relaxation of smooth muscle is dependent on nitric oxide (NO). 7 In response to sexual stimuli, cavernous nerves and endothelial cells release NO, which stimulates production of cyclic guanosine monophosphate (cGMP) through the action of guanylate cyclase. 5, 6 Cyclic guanosine monophosphate is subsequently hydrolyzed by cGMP-specific phosphodiesterase type 5 (PDE5), the predominant PDE in the corpus cavernosum, which in turn leads to detumescence. 8, 9 Sildenafil citrate (Viagra 1 -Pfizer Inc, New York, USA) is a novel, orally active agent that selectively inhibits cGMP-specific PDE5 with an IC 50 value of 3.5 nM. 9 -11 The pharmacodynamic and pharmacokinetic properties of sildenafil make it an attractive option for the treatment of ED. Sildenafil is rapidly absorbed, with a T max of approximately 1 h, and exhibits a short plasma half-life of 3 -5 h. 9 By preventing the hydrolysis of cGMP, sildenafil acts to maintain elevated levels of cGMP and facilitates the achievement and maintenance of erections. 9 The efficacy of oral sildenafil at doses from 25 mg to 100 mg has been demonstrated in previous double-blind, placebocontrolled, fixed-and flexible-dose studies conducted over a period of 3 -6 months. 12 Moreover, treatment with sildenafil was well tolerated. 12, 13 Sildenafil has a mild vasodilator effect over the therapeutic dose range of 25 mg to 100 mg and an affinity for retinal PDE6 that is approximately 10-fold less than for PDE5 (IC 50 ¼ 33 nM). 14 The most commonly reported adverse events (AEs) were consistent with the pharmacological mechanism of action of sildenafil, and included headache, flushing, dyspepsia, and abnormal vision. 12, 13 In this report, we present data on the long-term (36 -52 weeks) efficacy and safety of oral sildenafil in open-label, noncomparative, flexible-dose studies in men with ED of broad-spectrum etiology.
Patients and methods

Patient recruitment and study design
Male outpatients with ED of various etiologies were eligible for enrolment in long-term, open-label extension studies if they were at least 18 y of age, had completed a previous double-blind or openlabel study with sildenafil, and wished to continue receiving treatment. Four long-term studies were conducted, including one 36-week study and three 52-week studies. These studies had common protocols, including inclusion and exclusion criteria. The men who participated in these four studies were required to have a clinical diagnosis of ED of at least 3 months' duration prior to enrolment in the previous study and to have been in a stable relationship with a female partner for at least 6 months. Patients were excluded from either the earlier studies or the long-term extension studies if they had received anticoagulants, estrogens, androgens, anti-androgens, or major tranquilizers. The use of nitrates on a regular basis was not allowed for the duration of the study because of the suspected interaction between sildenafil and NO donors. However, a small number of patients did in fact use nitrates on an infrequent basis. Patients were also excluded from participating in any study if they had a medical history of major haematological, renal, or hepatic abnormalities, recent (within 6 months) major cardiovascular event, or peptic ulceration. Additional exclusion criteria included hypertension (blood pressure > 170=110 mm Hg) and postural hypotension (blood pressure < 90= 50 mm Hg), retinitis pigmentosa, or any clinically significant abnormality following review of results from a prestudy full physical examination and laboratory tests.
For patients who participated in the 36-week study, the starting dose of sildenafil was 25 mg. The starting dose of sildenafil for the 52-week studies was the patient's preferred dose as determined in earlier open-label studies, or 25 mg of sildenafil for subjects who had previously participated in doubleblind studies. Patients were instructed to take sildenafil as needed but not more than once daily. Clinic visits were scheduled at baseline and after 2, 4, 8, 12, 20, 28 and 36 weeks (36-week trial) or after 4, 8, 16, 24 , 36, and 52 weeks (52-week trials) during the studies. Based on the investigator's assessment of efficacy and tolerability, the dose of sildenafil could be adjusted to 25 mg, 50 mg, or 100 mg at each visit. In addition, a 75-mg dose of sildenafil (which is not an approved dose) was an option during the 52-week studies. Eligible patients who enrolled in the extension studies provided written informed consent before receiving the study drug.
The results from the four open-label extension studies represent all the long-term treatment data for sildenafil available at that time and were pooled to examine the long-term efficacy and safety of sildenafil in the largest number of patients possible. The 36-week and 52-week durations of these studies were considered to be representative of long-term therapy for ED. Prior to these studies, the longest exposure time for sildenafil had been 24 weeks for treatment taken on an as needed basis.
Efficacy and safety evaluations
Efficacy was assessed at the end of all four studies using global efficacy questions (GEQs) that asked patients about the effect of sildenafil on sexual function and about their satisfaction with treatment. At the end of the 36-week study, patients were asked 'are you satisfied with the effect the treatment is having on your erection?' At the end of the 52-week studies, responses to two GEQs were recorded, 'has the treatment you have been taking over the last 4 weeks improved your erections?' (GEQ A) and 'if the treatment you have been taking were freely available would you want to continue taking it?' (GEQ B). Patients who were enrolled in the three 52-week studies also completed a Sexual Function Questionnaire (SFQ) assessing aspects of erectile function at baseline and at the end of the study. The SFQ used in these studies was a precursor of the subsequently validated International Index of Erectile Function questionnaire. Responses to the seven questions of the SFQ were graded on a scale of 1 -5, with higher scores indicating better sexual function.
The analysis of efficacy included data from all patients who received at least one dose of sildenafil during the extension trials (intent-to-treat population). Data presented were pooled from all four extension studies. The analysis of the responses to the SFQ used a last-observation-carried-forward (LOCF) algorithm to generate endpoint data for patients with a baseline measurement and at least one measurement during the study.
Safety assessments included a comprehensive physical examination and measurement of sitting blood pressure and pulse rate. Standard laboratory safety tests were performed at screening, at each visit during the study, and at the end of treatment. A full physical exam and 12-lead electrocardiogram recording were performed at screening and at the end of treatment. The investigators recorded Efficacy and safety of Viagra 1 W Steers et al observed or volunteered adverse events (AEs) at each study visit. Serious AEs were considered to be those that: (1) were fatal; (2) were life-threatening; (3) resulted in permanent disability; (4) required hospitalization or prolongation of a hospital stay; (5) involved cancer, a congenital abnormality, or were the result of a drug overdose; or (6) were considered serious enough to be reported immediately by the investigator.
Results
Demographics
A total of 1008 patients were enrolled in the four studies; 337 patients were enrolled in the 36-week study, and 308, 192, and 171 patients were enrolled in the three 52-weeks studies, respectively. Age, etiology of ED, and significant medical history of the patients are summarized in Table 1 . The etiology of ED was equally distributed, with approximately one-third of patients having ED of organic, psychogenic, or mixed organic=psychogenic origin. ED etiology was determined by investigators for previous sildenafil studies in which these patients participated. The mean duration of ED was 4.7 y. Many of the patients had significant concomitant illnesses at the time that these studies were conducted, including hypertension, diabetes mellitus, heart, and vascular disease (Table 1) . Patients who received medication to control these illnesses were permitted to continue receiving treatment throughout the study.
This study included both responders and nonresponders to sildenafil from previous trials. Of the 1008 patients enrolled, 873 patients had previously participated in efficacy studies in which efficacy was assessed by a GEQ ('Has the treatment you have been taking over the last 4 weeks improved your erections?'). Responders were defined as patients who answered 'yes' and nonresponders as patients who answered 'no' to the GEQ. These 873 patients represented both responders (546=873, 62.5%) and nonresponders (327=873, 37.5%). These 873 patients also represented the majority (83.5%) of a total of 1045 patients who answered the GEQ and chose to continue into an extension study; both responders (74=172, 43%) and nonresponders (98=172, 57%) made up the remaining 172 patients who did not continue into an extension study.
In the 36-week study, 269 patients (80%) completed treatment with a median duration of therapy of 252 days. The median number of sildenafil doses taken was 99, with a median frequency of one dose every 2.5 days. In the 52-week studies, 565 patients (84%) completed treatment. In these studies, the mean duration of therapy was 358 days, the median number of sildenafil doses taken was 101 doses, and the mean frequency was one dose every 3.5 days.
The distributions of doses of sildenafil at the end of the 36-week and 52-week treatment periods are shown in Figure 1 . For the 36-week study, all patients were started at 25 mg of sildenafil. After 2 weeks of treatment, 99% of the patients were still taking the starting dose of 25 mg of sildenafil. Dosing increased with increasing time during the study: after 4 weeks of treatment, 88% of all patients were taking 50 mg of sildenafil and after 8 weeks of treatment, 77% of all patients were taking 100 mg of sildenafil. At the end of the treatment period (36 weeks), the percentage of patients receiving 100 mg of sildenafil had increased to 86%. Of the patients enrolled in the four studies, 51% preferred a dose of 100 mg sildenafil at the end of the treatment periods. 
Efficacy
Satisfaction with the effect of sildenafil on erections generally increased with increasing dose and duration of therapy. After 2 weeks of treatment during the 36-week study, 10% of all patients reported that treatment with sildenafil improved their erections (Figure 2 ). The rate of positive response to treatment increased to 24% of all patients after 4 weeks of treatment. With increasing time and dose, the percentage of patients reporting a satisfactory response to the treatment continued to increase. At the end of the treatment period, the percentage of patients reporting improved erections increased to 92% (Figure 2) .
At the end of the 52-week studies, 87% of patients reported that treatment with sildenafil had improved their erections (Figure 3 A) , and 91% of patients expressed a desire to continue taking sildenafil (Figure 3 B) .
Responses to the SFQ at baseline and at the end of the 52-week treatment periods are summarized in Table 2 . Clinical improvements were noted for questions addressing erectile function; the greatest increase in score was seen for the question addressing the duration of erections (Question 6). The mean score rose from the mean baseline score of 1.78 (2 ¼ 'a few times') to a final score of 3.79 (4 ¼ 'most times'), an increase of 112%. This was followed by increases in mean scores for questions addressing the firmness of erections (Question 5), which increased from the mean baseline score by 88%, and overall satisfaction with the sex life (Question 7), which rose from the mean baseline score by 81%. Study endpoint scores for questions addressing the frequency and rating of sexual desire (Questions 1 and 2) and the frequency of waking (ie unstimulated) erections (Question 3) were only slightly higher than scores at baseline, with increases ranging from 14% to 24% (Table 2 ). Only 5% of all patients enrolled in the four long-term studies discontinued treatment with sildenafil due to insufficient response (Table 3) .
Safety
Treatment with sildenafil was well tolerated. Only 16 patients (2%) discontinued treatment due to treatment-related AEs (Table 3) . Headache, dyspepsia, rhinitis, and abnormal vision were the most frequently reported treatment-related AEs leading to discontinuations. A total of 70 patients (7%) reduced the dose of sildenafil or temporarily discontinued treatment due to AEs. a Scores for all questions ranged from 1 (the worst response) to 5 (the best response). Endpoint scores were determined after 52 weeks of treatment with sildenafil.
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The most commonly occurring AEs of all causes were headache (14%), flushing (12%), dyspepsia (12%), rhinitis (4%), and abnormal vision (3%). Except for flushing, only half of these occurrences were considered to be related to treatment ( Figure  4 ). The treatment-related incidence of headache was 7%; flushing, 12%; dyspepsia, 8%; rhinitis, 2%; and abnormal vision, 2%. The majority of treatmentrelated AEs were transient and mild to moderate in nature. Severe treatment-related headache, dyspepsia, rhinitis, or flushing were experienced by 1% of patients. Other than for flushing, the incidence of treatment-related cardiovascular AEs (hypertension, tachycardia, palpitation, angina pectoris) was low ( 1%), and these events were generally transient and mild to moderate in severity. Abnormal vision was generally described as a predominantly minor color tinge to vision and increased sensitivity to light or blurred vision.
Serious AEs occurred in 69 patients (7%): the investigators did not consider any of these events related to the study drug. The most frequently occurring serious AEs included surgery, cancer, and viral chest infection. Two patients died during the study. One of the deaths was due to an acute myocardial infarction that occurred approximately 3 months after the diagnosis of metastatic pancreatic cancer in a man aged 65 y with history of myocardial infarction (20 y previously). The other death resulted from malignant melanoma. Neither death was considered to be related to the study drug.
The use of nitrates or NO donors was an exclusion criteria at entry for all studies, and routine use of nitrates during the extension studies was not permitted by protocol. However, an examination of patient case report forms indicates that 7 of 1008 patients (< 1%) received treatment with nitroglycerin and=or isosorbide mononitrate at some point during the extension studies. Adverse events that were reported for this group of patients are summarized in Table 4 .
Discussion
The results obtained from the analysis of data acquired in four long-term, open-label extension studies conducted for up to 52 weeks clearly demonstrate the long-term efficacy and safety of sildenafil for patients with ED of broad-spectrum etiology. At the end of the four studies, responses to two similarly worded GEQs showed that about 90% of patients were either satisfied with the effect that sildenafil had on their erections or reported that sildenafil had improved their erections over the last 4 weeks of treatment. The percentage of patients reporting that sildenafil had improved their erections in these open-label, long-term extension studies is in general agreement with results reported for short-term, double-blind, placebo-controlled studies with sildenafil. 12, 15 After 12 weeks of treatment with sildenafil in a double-blind, doseescalation study, 74% of the men reported improved erections (vs 19% for placebo). The same report also showed that, in a double-blind, dose -response study, 84% of the men reported improved erections a Non-treatment-related reasons including protocol violations, no follow-up visits, withdrawn consent and personal reasons. Figure 4 The most commonly occurring ( 3% incidence) allcause and treatment-related adverse events occurring during longterm sildenafil treatment. The occurrence of adverse events relative to the time sildenafil and nitrates were taken is not known. Event was judged by investigator to be unrelated to treatment.
Efficacy and safety of Viagra Although the percentage of patients with improved erections in the four long-term studies reported here is somewhat higher than that reported in the earlier short-term, double-blind studies, this was not unexpected. Most of the patients enrolled in the open-label studies had reported that treatment with sildenafil improved their erections in the previous studies and further expressed a desire to continue treatment with sildenafil. However, it is noteworthy that the efficacy of sildenafil did not appear to diminish with long-term use. There was no evidence that tolerance to sildenafil developed on long-term exposure to the drug when taken as recommended. Only 5% of patients discontinued treatment due to insufficient therapeutic response.
The study results indicate that the response to sildenafil improves over time. The 36-week study found an improvement in response to sildenafil with increasing dose and duration of treatment, with the rate of improved erections increasing from 10% after 2 weeks of treatment to 92% after 36 weeks of treatment. The improved response rate may reflect the use of 100 mg doses of sildenafil by a high proportion of patients (86%) by the end of the 36-week study. In contrast, at the end of the 52-week studies, only 37% of patients were taking 100 mg of sildenafil, yet the overall rate of improved erections (87%) was similar to that in the 36-week study (92%). The reason for the more frequent use of 100 mg doses of sildenafil in the 36-week study compared with the 52-week studies cannot be explained. One could speculate that the severity of ED among patients enrolled in the 36-week study may have been greater than that among patients enrolled in the 52-week studies, necessitating a greater increase in sildenafil dose to achieve similar responses. Drug cost was not a treatment-limiting factor, as sildenafil was supplied free of charge for the duration of all the studies. In clinical practice, however, some patients may find cost to be an occasional limitation to the use of sildenafil.
During the 52-week studies, an optional dose of 75 mg sildenafil was permitted. Although this dose has been studied in a few clinical trials, a 75 mg dose of sildenafil is not an approved dose.
Sildenafil was also well tolerated in these longterm studies, even at the highest recommended therapeutic dose (100 mg). At the end of the treatment periods, 56% of all patients were taking 100 mg doses of sildenafil. The incidence, type, and severity of AEs reported in these long-term, openlabel, extension studies were comparable to those reported in short-term, double-blind, placebocontrolled clinical trials. 12, 13, 15 The most common AEs of all causes in the open-label studies were headache, flushing, and dyspepsia, which occurred in 14%, 12%, and 12% of patients, respectively. Transient abnormal vision was reported by 3% of patients in the open-label studies. Furthermore, treatment discontinuations were low, with 16 patients (2%) discontinuing treatment due to treatment-related AEs. This result is in agreement with results obtained previously from three 12-week flexible-dose studies. 12, 13, 15 In these studies, only 1% of patients discontinued treatment due to treatment-related AEs. Treatment with sildenafil for an extended period, as shown in the studies reported here, did not increase the proportion of patients discontinuing treatment due to AEs.
A variety of medical conditions and lifestyle factors can contribute to the development of ED, including hypertension, diabetes, hyperlipidemia, depression, and smoking. 4 Moreover, ED is a common disorder in older men who are also at increased risk for cardiovascular disease. 4 Since there is an inherent risk of adverse cardiovascular events associated with sexual activity, and as sildenafil has modest vasodilator properties, 16 the cardiovascular safety profile of sildenafil in patients with a history of cardiovascular disorders is of particular interest. The studies reported here enrolled a substantial number of patients with a history of vascular and=or cardiovascular disease. These patients were allowed to continue receiving treatment for their particular diseases during the studies. The overall incidence of cardiovascular AEs other than flushing, such as hypertension and tachycardia, was low in all patients. Only three patients (0.3%) experienced severe cardiovascular AEs that were considered to be treatment related; all three were incidents of flushing. Results from this study do not demonstrate an increased risk for cardiovascular AEs with long-term sildenafil treatment for ED. However, the use of any treatment for ED, including sildenafil, is not advised for patients with underlying cardiovascular disease that increases the potential cardiac risk of sexual activity.
Patients with coronary heart disease, particularly angina pectoris, are often treated with organic nitrates, which improve the balance between myocardial oxygen supply and demand. Exogenously administered nitrates act through the NO-cGMP pathway and can significantly reduce systemic blood pressure and may cause episodes of postural hypotension. 17 The mechanism of action of sildenafil also involves the NO-cGMP pathway, and treatment with sildenafil may result in mild and transient decreases in blood pressure (mean maximum decrease of 8=6 mm Hg). 18 Also, when organic nitrates or NO donors are coadministered with sildenafil, a potentiation of the vasodilator effects of sildenafil is observed. 19 Due to the potential risk for developing hypotension, patients were excluded from participating in Phase II and Phase III trials of sildenafil if they were also taking organic nitrates routinely. These patients were similarly excluded from participating in the long-term studies reported here. However, seven patients (0.7%) took oral nitrates on an infrequent basis during these studies. Of these seven patients, two had an episode of angina pectoris, and one patient experienced a myocardial infarction. The relationship of these events to the time nitrates were taken and the last time sildenafil was taken is not known; however, administration of sildenafil is contraindicated in patients who are using organic nitrates in any form, either regularly or intermittently, because sildenafil has been shown to potentiate the hypotensive effects of nitrates. 20 
Conclusions
The results of these open-label studies indicate that the efficacy of sildenafil, taken as needed but not more than once daily, does not diminish with longterm use (1 y of treatment) and that the treatment response may improve over time. Furthermore, the long-term safety profile, including frequency, type, and severity of AEs, is similar to that reported in short-term, double-blind, placebocontrolled studies.
